

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of Cayman Islands with limited liability)

(Stock Code: 6833)

- (1) RESIGNATION OF CHAIRMAN OF THE BOARD,
EXECUTIVE DIRECTOR, CHAIRMAN OF NOMINATION COMMITTEE
AND AUTHORISED REPRESENTATIVE;
(2) CHANGE OF AUTHORISED REPRESENTATIVE; AND
(3) NON-COMPLIANCE WITH RULE 3.27A OF THE LISTING RULES**

RESIGNATION OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR, CHAIRMAN OF NOMINATION COMMITTEE AND AUTHORISED REPRESENTATIVE

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) announces that Mr. Huang Xiangbin (“**Mr. Huang**”) has tendered his resignation as the chairman of the Board, an executive Director, the chairman of the nomination committee of the Board (the “**Nomination Committee**”) and an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), with effect from 30 April 2026, as he wishes to dedicate more time and attention to his other commitments.

Mr. Huang confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its sincere gratitude and appreciation to Mr. Huang for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF AUTHORISED REPRESENTATIVE

The Board is pleased to announce that Mr. Huang Zhijian has been appointed as the Authorised Representative with effect from 30 April 2026. He is currently the vice chairman of the Board and an executive Director.

The Board would like to extend its warm welcome to Mr. Huang Zhijian on his new appointment.

NON-COMPLIANCE WITH RULE 3.27A OF THE LISTING RULES

Upon the resignation of Mr. Huang and as the new chairman of the Nomination Committee has not been appointed, the position will remain vacant. The Company is therefore not in compliance with Rule 3.27A of the Listing Rules which stipulates that an issuer must establish a nomination committee chaired by the chairman of the Board or an independent non-executive Director.

As such, pursuant to Rule 3.27C of the Listing Rules, the Board will make its best endeavours to identify appropriate person for appointment as the chairman of the Nomination Committee, as soon as practicable and, in any event, within three months from the date of Mr. Huang's resignation. The Company will make further announcement(s) as and when appropriate.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Zhijian
Vice Chairman and Executive Director

Sichuan, the PRC, 30 April 2026

As at the date of this announcement, the executive Directors are Mr. Huang Zhijian and Mr. Lei Shifeng; the non-executive Director is Ms. Jing Huan; and the independent non-executive Directors are Mr. Bai Zhizhong, Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang.